CN V3 Supplements - Related

The FDA set a Prescription Drug User Fee act date in the second quarter of 2025 for durvalumab plus chemotherapy in muscle-invasive bladder cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The FDA is expected to decide on approving glofitamab in relapsed or refractory diffuse large B-cell lymphoma by July 20, 2025.

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.